Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Time-critical stabilization
Airway and ventilation
High-flow oxygen for hypoxemia
Early intubation for refractory agitation, hyperthermia, severe acidosis, impending respiratory failure
Circulation
Two large-bore IVs
Cardiac monitor
Temperature control
Active external cooling for hyperthermia
Avoid salicylates for antipyresis
Early ICU activation
Persistent hyperthermia
Shock
Ventricular arrhythmia
Altered mental status
Recognition and triggers
High-risk syndrome recognition
Thyrotoxic crisis phenotype
Hyperthermia
Marked tachycardia
CNS dysfunction
Heart failure
Common precipitants
Infection
Thyroid surgery or radioiodine
Withdrawal of antithyroid therapy
Iodine load
Trauma
Acute coronary syndrome
Monitoring and targets
Physiologic targets
Hemodynamics
Mean arterial pressure appropriate for perfusion
Heart rate control without shock
Temperature
Down-trending core temperature within 1-2 hours
Avoid overcooling
Glucose
Avoid hypoglycemia during high metabolic demand
Early consults
Specialist coordination
Endocrinology
Antithyroid selection and definitive therapy planning
Critical care
Vasopressors, ventilation, advanced temperature management
Cardiology
Atrial fibrillation with instability
Refractory rate control
Surgery
Suspected thyroiditis abscess
Consider urgent thyroidectomy in refractory cases
History
Presentation pattern
Classic presentation
Acute decompensation in known or unrecognized thyrotoxicosis
Fever
Palpitations
Multisystem involvement
Delirium or agitation
Dyspnea or edema
Precipitating factors
Triggers and exposures
Infection symptoms
Respiratory
Urinary
Recent iodine exposure
Iodinated contrast
Amiodarone
Recent thyroid manipulation
Surgery
Biopsy
Thyroid disease context
Thyroid history
Graves disease history
Prior thyroid levels
Prior orbitopathy
Toxic nodular goiter history
Longstanding goiter
Prior compressive symptoms
Medication history
Medications and adherence
Antithyroid drugs
Missed doses
Recent dose changes
Beta-blockers
Recent discontinuation
Intolerance
Drugs that worsen tachycardia
Sympathomimetics
Cocaine or stimulants
Physical Exam
Vital signs and general
High-yield findings
Hyperthermia pattern
Core temperature elevation
Diaphoresis
Cardiovascular stress
Marked tachycardia
Wide pulse pressure
Cardiopulmonary
Cardiac and pulmonary
Arrhythmia assessment
Atrial fibrillation
Ventricular ectopy
Heart failure signs
Pulmonary edema
Elevated JVP
Neurologic and mental status
CNS involvement
Agitation or delirium
Disorientation
Psychosis
Severe features
Seizure
Coma
Thyroid and eye
Thyroid exam
Goiter features
Diffuse enlargement
Nodularity
Thyroid tenderness
Subacute thyroiditis consideration
Eye and skin
Graves features
Lid lag
Proptosis
Pretibial myxedema
Localized dermopathy
Differential Diagnosis
Life-threatening mimics
Critical mimics
Sepsis (ICD-10 A41.9)
Fever with shock
Elevated lactate
Serotonin syndrome (ICD-10 T43.24XA)
Clonus
Hyperreflexia
Neuroleptic malignant syndrome (ICD-10 G21.0)
Rigidity
Recent dopamine antagonist exposure
Overlapping hyperthermia syndromes
Hyperthermia syndromes
Heat stroke (ICD-10 T67.0)
Hot dry skin possible
Environmental exposure
Malignant hyperthermia (ICD-10 T88.3)
Peri-anesthetic timing
Severe rigidity
Cardiac primary processes
Primary cardiac diagnoses
Acute coronary syndrome (ICD-10 I21.9)
Chest pain
Ischemic ECG
Decompensated heart failure (ICD-10 I50.9)
Pulmonary edema
Low output state
Thyroid-related differentials
Thyroid causes
Thyrotoxicosis without storm (ICD-10 E05.90)
Mild CNS symptoms absent
Hemodynamic stability
Thyroiditis (ICD-10 E06.9)
Tender thyroid
Elevated ESR or CRP
Laboratory Tests
Core labs
Baseline evaluation
Thyroid function
TSH
Free T4
Total T3 or free T3
Metabolic panel
Sodium
Potassium
Creatinine
Hepatic panel
AST
ALT
Bilirubin
Severity and complications
Complication screening
Venous blood gas
pH
Lactate mmol/L
Glucose mmol/L
Stress hyperglycemia
Hypoglycemia risk in liver failure
CBC
Leukocytosis in infection or stress
Baseline before thionamides
Etiology and precipitant workup
Trigger evaluation
Blood cultures if sepsis concern
Pre-antibiotic draw if feasible
Persistent fever despite therapy
Urinalysis and culture
Urinary symptoms
Elderly with delirium
Respiratory viral testing when relevant
Influenza season
COVID-19 circulation
Treatment safety labs
Medication risk monitoring
Baseline ANC surrogate
Neutrophil count
Fever or sore throat during therapy as agranulocytosis trigger
Coagulation studies
INR for hepatic dysfunction
Procedural planning
Diagnostic Tests
Scoring Systems
Diagnostic support tools
Burch-Wartofsky Point Scale (BWPS)
Thermoregulatory dysfunction points
Increasing points with higher temperature
High scores support storm likelihood
CNS effects points
Agitation or delirium
Seizure or coma
Cardiovascular dysfunction points
Tachycardia severity
Heart failure severity
Precipitating event points
Infection or surgery
Trauma
Japanese Thyroid Association criteria
Thyrotoxicosis requirement
Elevated free T4 or T3
Suppressed TSH
System involvement combinations
CNS symptoms
Fever
Tachycardia
Heart failure
GI or hepatic dysfunction
MRI
MRI indications
Alternate CNS diagnosis evaluation
Focal neurologic deficit
Persistent altered mental status not explained by storm severity
MRI constraints
Hemodynamic instability limits feasibility
Time-sensitive stabilization priority
CT
CT use cases
Suspected pulmonary embolism alternative
Pleuritic pain
Unexplained hypoxemia
Intra-abdominal trigger search
Severe abdominal pain
Concern for perforation or abscess
Ultrasound (or US)
Ultrasound applications
Cardiac POCUS
LV function
Pulmonary edema pattern
Thyroid ultrasound
Nodular goiter assessment when stable
Thyroiditis features with tenderness
Lung ultrasound
B-lines
Pleural effusion
Disposition
Level of care
Disposition decisions
ICU admission criteria
BWPS high probability with organ dysfunction
Need for continuous IV beta-blocker infusion
Step-down consideration
Rapid improvement after therapy
No heart failure
Transfer and escalation
Transfer triggers
Lack of ICU capability
Mechanical ventilation needs
Refractory shock
Need for definitive thyroid therapy not available
Urgent thyroidectomy capability
Plasmapheresis access for refractory cases
Discharge criteria
Discharge exceptions
Thyrotoxicosis without storm only
Stable vitals after observation
Reliable follow-up within 24-72 hours
Treatment
Core strategy and sequence
Five-pillar treatment sequence
Supportive care and cooling
Airway and oxygenation
Isotonic fluids with cautious titration in heart failure
Adrenergic blockade
Rate control goal without hypotension
Avoid isolated calcium channel blocker in shock
Thionamide to block synthesis
PTU or methimazole selection
Early administration priority
Iodine to block release
After thionamide timing
Avoid before thionamide in most cases
Glucocorticoid to reduce T4 to T3 and treat adrenal insufficiency risk
Hydrocortisone preferred
Stress-dose strategy
Antipyresis and cooling
Temperature management
Cooling modalities
Cooling blankets
Ice packs to groin and axilla
Antipyresis
Acetaminophen dosing per local protocol
Avoid aspirin and salicylates
Beta-blockade
Adrenergic blockade options
Propranolol PO or IV
Typical strategy
Oral dosing in stable patients
IV dosing for rapid control in monitored setting
Additional benefit
Reduced peripheral T4 to T3 conversion at higher doses
Esmolol IV infusion
Initiate for severe tachycardia with titratable short half-life
Loading bolus per local protocol
Continuous infusion titration every 5-15 minutes
Stop if hypotension or worsening shock
Transition to alternative rate control
Vasopressor support if needed
Contraindications and cautions
Decompensated heart failure
Asthma with bronchospasm
Shock or low output state
Thionamides
Antithyroid drugs
Propylthiouracil (PTU)
Dosing strategy
Loading dose then scheduled dosing
Enteral route preferred when possible
Rationale
Blocks thyroid hormone synthesis
Decreases peripheral T4 to T3 conversion
Safety considerations
Hepatotoxicity risk
CBC and LFT monitoring
Methimazole
Dosing strategy
High-dose scheduled regimen
Enteral route preferred when possible
Rationale
Blocks thyroid hormone synthesis
Lower severe hepatotoxicity risk than PTU in many settings
Pregnancy note
Avoid in first trimester when possible
Preferred in second and third trimester
Iodine therapy
Iodine blockade
Timing
Administer at least 1 hour after thionamide when feasible
Earlier use if life-threatening and thionamide delayed only with specialist input
Formulations
Potassium iodide solution
Lugol solution
Iodinated contrast effect acknowledgement
Contraindications and pitfalls
Iodine allergy is not equivalent to contrast reaction history
Use caution in toxic nodular disease with recent iodine load
Glucocorticoids
Steroid therapy
Hydrocortisone IV
Stress-dose regimen
Scheduled dosing for first 24-48 hours
Taper as clinical improvement occurs
Rationale
Reduced peripheral T4 to T3 conversion
Relative adrenal insufficiency coverage
Dexamethasone IV alternative
Use when mineralocorticoid effect undesirable
Longer half-life allows less frequent dosing
Adjunctive therapies
Additional hormone-lowering options
Cholestyramine
Enteral adjunct for severe cases
Binds thyroid hormones in gut
Shortens hormone half-life
Separation from other oral meds
Dose spacing to avoid reduced absorption
Lithium carbonate
Consider when thionamides contraindicated
Blocks hormone release
Narrow therapeutic window
Monitoring needs
Serum lithium levels
Renal function
Plasmapheresis
Consider for refractory storm
Severe hepatic failure limiting drug options
Bridge to thyroidectomy
Arrhythmia and heart failure management
Cardiovascular complications
Atrial fibrillation
Beta-blocker first-line when hemodynamically tolerated
Esmolol in ICU setting
Propranolol in stable setting
Digoxin considerations
Reduced efficacy in thyrotoxicosis
Higher dose requirements increase toxicity risk
Amiodarone considerations
Iodine load may worsen thyroid status
Use only with specialist input for life-threatening arrhythmia
Heart failure
Diuretics for pulmonary edema
Loop diuretic titration based on response
Monitor electrolytes
Vasopressors for shock
Norepinephrine as typical first-line in distributive physiology
Avoid excessive beta-agonism when possible
Antibiotics and trigger treatment
Precipitant-directed therapy
Sepsis bundle when suspected
Early broad-spectrum antibiotics
Source control plan
ACS management when suspected
ECG-guided therapy
Troponin trend and cardiology input
Evidence levels
Evidence grading notes
ACEP clinical policy specific to thyroid storm not established
Many interventions based on endocrine society guidance and expert consensus
ACEP Level C style evidence alignment for ED pathways in absence of RCTs
Class recommendations framework
Class I
Supportive care and cooling for hyperthermia
Beta-blockade when hemodynamically tolerated
Thionamide then iodine sequence
Glucocorticoids early in severe storm
Class IIa
Cholestyramine adjunct in severe cases
Esmolol infusion for titratable control in ICU
Class IIb
Plasmapheresis for refractory cases as bridge to definitive therapy
Special Populations
Pregnancy
Pregnancy considerations
Maternal-fetal risks
Preterm labor risk
Fetal tachycardia risk
Antithyroid selection
PTU preferred in first trimester
Methimazole preferred after first trimester
Beta-blocker cautions
Fetal growth restriction with prolonged use
Neonatal bradycardia risk
Geriatric
Older adult considerations
Atypical presentation
Afebrile storm possible
Predominant heart failure
Medication sensitivity
Lower beta-blocker tolerance
Higher delirium risk with sedatives
Comorbidity triggers
Pneumonia
Atrial fibrillation onset
Pediatrics
Pediatric considerations
Weight-based dosing
Thionamide dosing per kg
Beta-blocker dosing per kg
Etiologies
Graves disease most common
Thyroiditis less common
Monitoring intensity
Rapid decompensation risk
Early ICU involvement threshold lower
Background
Epidemiology
Population patterns
Rarity
Uncommon complication of thyrotoxicosis
Higher risk with untreated Graves disease
Mortality
High mortality without rapid recognition and treatment
Outcomes improve with early ICU-level care
Coding alignment
ICD-10 E05.01 thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm
ICD-10 E05.11 toxic single thyroid nodule with thyrotoxic crisis or storm
Pathophysiology
Mechanistic framework
Excess circulating thyroid hormone effect
Increased beta-adrenergic receptor expression
Increased metabolic rate and heat production
Decompensation model
Precipitant increases hormone release or demand
Limited cardiovascular reserve leads to failure
Organ dysfunction pathways
High-output heart failure progression
Hepatic hypoperfusion and cholestasis
Therapeutic Considerations
Rationale for sequencing
Thionamide before iodine
Prevents iodine-driven hormone synthesis
Supports Wolff-Chaikoff benefit while limiting substrate effect
Beta-blockade early
Symptom control and arrhythmia prevention
Avoids catecholamine-mediated injury
Steroids early
Reduced T4 to T3 conversion
Adrenal support in critical illness
Definitive therapy planning
Radioiodine timing after stabilization
Thyroidectomy consideration for refractory storm or contraindications
Patient Discharge Instructions
Copy discharge instructions
Discharge instructions template
Diagnosis clarification
Thyrotoxicosis without storm diagnosis only
Thyroid storm requires admission and ICU monitoring
Medications
Antithyroid medication adherence as prescribed
Beta-blocker adherence as prescribed
Return to ED now
Fever
Chest pain
Shortness of breath
Fainting
Confusion or severe agitation
Persistent vomiting
Follow-up
Endocrinology follow-up within 24-72 hours
Repeat thyroid labs per plan
References
Clinical guidelines and consensus
Key guidance sources
American Thyroid Association guidance on thyrotoxicosis and antithyroid drugs
PTU versus methimazole pregnancy recommendations
Agranulocytosis counseling emphasis
Japanese Thyroid Association criteria for thyroid storm
Diagnostic combinations with thyrotoxicosis requirement
Severity stratification supporting ICU care
Evidence-based sources
Evidence base
Burch-Wartofsky Point Scale primary description
Multisystem point-based probability approach
Use as adjunct, not replacement for clinical judgment
Reviews and critical care summaries on storm treatment sequencing
Thionamide then iodine consensus sequence
Steroid role in T4 to T3 reduction
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.